Remove 2014 Remove Competition Remove Sales
article thumbnail

470% price increases

World of DTC Marketing

net revenue for Imbruvica has increased from $492 million in 2014 to $4.3 billion in Imbruvica net revenue from Medicare Part D between 2014 and 2018. AbbVie has obtained or applied for over 250 patents on Humira to block competition from lower-priced biosimilars. AbbVie’s yearly U.S. billion in 2020. billion in 2020.

article thumbnail

The Fastest Growing Companies in Boston Hiring For Sales

CloserIQ

Boston is emerging as one of the hottest startup cities in the country, which is great news for sales professionals. These companies are all backed by venture capital and are currently hiring in sales roles. This is by no means an exhaustive list, but here are some great companies to consider for your next sales job. ProfitWell.

Sales 76
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How Value Based Health Care Will Impact Medical Sales

Spotio

The goals are to increase quality, decrease costs and turn health care into a competitive marketplace. They cite a 24% increase in drug costs per hospital admission in 2014 and a 12% increase in 2015. Home healthcare won’t directly impact medical device sales. Better health outcomes will drive sales.

article thumbnail

Oncology biosimilar case studies: rituximab biosimilars

Pharmaceutical Technology

Rituxan received its first FDA approval in 1997 for the treatment of B-cell non-Hodgkin’s lymphoma (B-NHL) and reached peak global sales of $7.5bn in 2014. Rituximab biosimilars have since achieved notable commercial success, with global sales surpassing $900m collectively.

Sales 59
article thumbnail

Pharma says VPAS clawback jeopardises UK sector

pharmaphorum

of total sales – under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) introduced in 2019. ” Since 2014, the repayment percentage detailed in the VPAS and predecessor the PPRS average at around 7%, before skyrocketing to 19% in 2022 ahead of a government agreed cap at 15%. The increase to 26.5%

Pharma 72
article thumbnail

Call to arms as UK falls back in medicines manufacturing

pharmaphorum

A just-published report from the Medicines Manufacturing Industry Partnership (MMIP) – set up by the UK government and biopharma industry in 2014 to drive growth in the category – says the sector has the potential to be a driver for the UK economy in the next decade.

article thumbnail

UK authority asks for director ban for Alliance Pharma CEO

pharmaphorum

The UK Competition and Markets Authority (CMA) is seeking to disqualify Peter Butterfield, currently chief executive of Alliance Pharma, from serving as a company director. ” The action will only be heard if the Competition Appeal Tribunal (CAT) upholds the CMA’s findings against Alliance, it added. .”

Pharma 59